direct thrombin inhibitor


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

direct thrombin inhibitor

Abbreviation: DP
Any medication or substance that interferes with the coagulation of blood by blocking the action of thrombin. Unlike heparins, which are anticoagulants that require the presence of antithrombin to inactivate thrombin, DTIs exert their effects without an intermediary. DTIs can be used to treat and prevent clots in both arteries and veins (although heparin and warfarin are usually preferred for these uses). They are an alternative to heparin in patients with a history of heparin-induced thrombocytopenia. The primary side effect of DTIs is bleeding.
See also: inhibitor
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Wei, "Direct thrombin inhibitors: patents 2002-2012 (review)," Molecular Medicine Reports, vol.
Illanes et al., "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran," Stroke, vol.
Newer oral anticoagulants, such as direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban), have been developed to overcome these drawbacks, and thereby improve patient care.
Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
The direct thrombin inhibitor dabigatran appears to raise the risk of myocardial infarction or acute coronary syndromes, according to a meta-analysis of seven randomized trials.
(2,5,10,17) A direct thrombin inhibitor (DTI) must be administered for a minimum of 7 days.
Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers, following intravenous, subcutaneous and oral administration.
Demographics of Direct Thrombin Inhibitor Use in Pediatric Patients Category Argatroban Bivalirudin (n = 144) (n = 48) Age category, No.
According to the company, Angiox is a direct thrombin inhibitor and is indicated in Europe as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
In addition to the current study of rivaroxaban, they also cited the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) study, which showed that "dabigatran, a direct thrombin inhibitor, was not inferior to warfarin."
* Ximelagatran, a direct thrombin inhibitor, appeared to hold promise as an oral anti-coagulant, but was denied FDA approval and eventually withdrawn by its manufacturer when reports of hepatotoxicity and possible myocardial ischemia surfaced.